Welcome to our dedicated page for INSMED SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
INSM filed a Form 144 disclosing sales of Common stock by William Lewis. The filing lists multiple reported sale entries under Stock Plan Activity and a section titled Securities Sold During The Past 3 Months, with dated line items ranging from 12/18/2025 to 03/05/2026.
INSMED Inc Chair and CEO William Lewis reported multiple transactions in company stock. On 2026-03-05, he exercised stock options for 6,259 and 4,440 shares of common stock through derivative conversions. He then sold a total of 10,699 common shares in open-market transactions at weighted average prices noted in the filing, effected under a Rule 10b5-1 trading plan adopted on September 4, 2025. After these trades, he held 301,185 common shares directly and 233,924 common shares indirectly through the Katie Procter Dynasty Trust as of that date.
INSMED Inc director Melvin Sharoky, MD reported a bona fide gift of common stock. On March 3, 2026, an entity associated with him transferred 100 shares of common stock as a gift transfer at a reported price of $0.0000 per share, reducing his directly held shares to 242,776.
He also reported several indirect holdings: 6,847 shares held by his spouse, 5,000 shares held by Padonia, LLC, where he is the managing member, and custodial UTMA/FL accounts holding 819, 5,423, 5,007, and 3,724 shares for named family beneficiaries.
Insmed Inc director Melvin Sharoky reported several bona fide gifts of common stock dated February 25, 2026. He gifted 1,072 shares from his direct holdings and 243 shares to each of four UTMA custodial accounts for family members. After these gifts, he continued to hold 242,876 shares directly, while indirect holdings included shares in custodial UTMA accounts, 5,000 shares held through Padonia, LLC, and 6,847 shares held by his spouse.
Insmed Inc’s Chief Legal Officer, Michael Alexander Smith, reported option exercises and share sales in company stock. On February 24, 2026, he exercised a stock option for 20,248 shares, converting a derivative security into common stock at a reported price of $17.07 per share.
On the same date, he sold a total of 24,774 shares of common stock in open-market transactions at weighted average prices of $153.93, $155.06, and $156.53 per share, under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he directly owned 51,871 common shares of Insmed.
INSMED Inc director David R. Brennan reported a bona fide gift of 6,000 shares of Common Stock. The gift was made on February 23, 2026 at a reported price of $0.00 per share, indicating it was a non-cash, charitable or personal transfer rather than a sale.
After this disposition, Brennan directly holds 60,933 shares of INSMED Common Stock. In addition, an indirect holding of 60,000 shares is reported as being held by a spouse revocable trust, reflecting shares associated with, but not directly owned by, the director.
INSM filed a Form 144 disclosing recent resale notices and issuer stock plan activity. The filing lists multiple issuer plan issuances on 01/04/2026, 01/05/2026, 01/06/2026, 02/01/2026, and 02/24/2026 with amounts of 1,554, 874, 1,312, 786, and 20,248 shares respectively.
The filing also shows sales by Michael Smith on 01/06/2026 (1,396 shares), 01/07/2026 (709 shares), 01/08/2026 (1,053 shares), and 02/04/2026 (640 shares). The excerpt lists 215,551,896 shares outstanding as of 02/24/2026.
Insmed Inc Chair and CEO William Lewis reported option exercises and share sales. On February 19, 2026, he exercised stock options for 6,259 and 4,440 shares, converting them into an equal number of Common Stock shares at grant prices of $30.46 and $17.16 per share.
On the same date, he sold a total of 10,699 Common Stock shares in open-market transactions at weighted average prices between $149.17 and $153.38, under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 4, 2025. After these trades, he held 301,185 shares directly, plus indirect holdings of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
INSM filings report insider stock sales by William Lewis. The filing lists multiple sales dated between 12/04/2025 and 02/19/2026, with reported sale amounts including 13,396, 3,009, 10,699, 19,215, 3,223, 2,357, 4,096, and other similar share quantities. The entries show transaction dates and numeric amounts associated with each sale.
Insmed Incorporated uses this Annual Report to outline its strategy as a global biopharma company focused on respiratory, immunology & inflammation, and neuro & other rare diseases. The company now has two commercial respiratory drugs: ARIKAYCE, an inhaled therapy for MAC lung disease with approvals in the US, Europe and Japan, and BRINSUPRI, an oral treatment for non-cystic fibrosis bronchiectasis approved in the US in August 2025 and by the European Commission in November 2025.
Insmed highlights large addressable markets in bronchiectasis and MAC lung disease and reports positive Phase 3 data for brensocatib (ASPEN) and positive Phase 2 results for TPIP in pulmonary arterial hypertension and PH-ILD, with multiple Phase 3 programs planned in 2026. Early-stage gene therapy programs INS1201 for Duchenne muscular dystrophy and INS1202 for ALS are in Phase 1 trials, while the ARIKAYCE post-marketing ENCORE study is fully enrolled with topline data expected by April 2026 to support potential full US approval and label expansion.